vs
科睿唯安（CLVT）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
科睿唯安的季度营收约是ICU MEDICAL INC的1.1倍（$585.5M vs $540.7M），ICU MEDICAL INC净利率更高（-2.9% vs -6.9%，领先4.0%），科睿唯安同比增速更快（-1.4% vs -14.1%），科睿唯安自由现金流更多（$78.9M vs $36.0M），过去两年ICU MEDICAL INC的营收复合增速更高（-2.3% vs -5.1%）
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
CLVT vs ICUI — 直观对比
营收规模更大
CLVT
是对方的1.1倍
$540.7M
营收增速更快
CLVT
高出12.8%
-14.1%
净利率更高
ICUI
高出4.0%
-6.9%
自由现金流更多
CLVT
多$42.9M
$36.0M
两年增速更快
ICUI
近两年复合增速
-5.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $585.5M | $540.7M |
| 净利润 | $-40.2M | $-15.7M |
| 毛利率 | 67.2% | 37.5% |
| 营业利润率 | — | 1.0% |
| 净利率 | -6.9% | -2.9% |
| 营收同比 | -1.4% | -14.1% |
| 净利润同比 | -163.1% | 34.0% |
| 每股收益（稀释后） | $-0.06 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLVTICUI
| Q1 26 | $585.5M | — | ||
| Q4 25 | $617.0M | $540.7M | ||
| Q3 25 | $623.1M | $537.0M | ||
| Q2 25 | $621.4M | $548.9M | ||
| Q1 25 | $593.7M | $604.7M | ||
| Q4 24 | $663.0M | $629.8M | ||
| Q3 24 | $622.2M | $589.1M | ||
| Q2 24 | $650.3M | $596.5M |
净利润CLVTICUI
| Q1 26 | $-40.2M | — | ||
| Q4 25 | $3.1M | $-15.7M | ||
| Q3 25 | $-28.3M | $-3.4M | ||
| Q2 25 | $-72.0M | $35.3M | ||
| Q1 25 | $-103.9M | $-15.5M | ||
| Q4 24 | $-191.8M | $-23.8M | ||
| Q3 24 | $-65.6M | $-33.0M | ||
| Q2 24 | $-304.3M | $-21.4M |
毛利率CLVTICUI
| Q1 26 | 67.2% | — | ||
| Q4 25 | 66.8% | 37.5% | ||
| Q3 25 | 65.0% | 37.4% | ||
| Q2 25 | 67.2% | 37.9% | ||
| Q1 25 | 65.1% | 34.7% | ||
| Q4 24 | 65.7% | 36.1% | ||
| Q3 24 | 66.2% | 34.8% | ||
| Q2 24 | 67.2% | 34.8% |
营业利润率CLVTICUI
| Q1 26 | — | — | ||
| Q4 25 | 6.7% | 1.0% | ||
| Q3 25 | 7.1% | 2.6% | ||
| Q2 25 | 1.1% | 1.9% | ||
| Q1 25 | -3.5% | 2.1% | ||
| Q4 24 | -9.4% | 6.0% | ||
| Q3 24 | 3.5% | 1.4% | ||
| Q2 24 | -36.9% | 1.3% |
净利率CLVTICUI
| Q1 26 | -6.9% | — | ||
| Q4 25 | 0.5% | -2.9% | ||
| Q3 25 | -4.5% | -0.6% | ||
| Q2 25 | -11.6% | 6.4% | ||
| Q1 25 | -17.5% | -2.6% | ||
| Q4 24 | -28.9% | -3.8% | ||
| Q3 24 | -10.5% | -5.6% | ||
| Q2 24 | -46.8% | -3.6% |
每股收益（稀释后）CLVTICUI
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $0.00 | $-0.63 | ||
| Q3 25 | $-0.04 | $-0.14 | ||
| Q2 25 | $-0.11 | $1.43 | ||
| Q1 25 | $-0.15 | $-0.63 | ||
| Q4 24 | $-0.27 | $-0.97 | ||
| Q3 24 | $-0.09 | $-1.35 | ||
| Q2 24 | $-0.46 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | $4.3B | — |
| 股东权益账面价值 | $4.8B | $2.1B |
| 总资产 | $10.9B | $4.1B |
| 负债/权益比越低杠杆越低 | 0.89× | — |
8季度趋势，按日历期对齐
现金及短期投资CLVTICUI
| Q1 26 | — | — | ||
| Q4 25 | $329.2M | — | ||
| Q3 25 | $318.7M | — | ||
| Q2 25 | $362.6M | — | ||
| Q1 25 | $354.0M | — | ||
| Q4 24 | $295.2M | $308.6M | ||
| Q3 24 | $388.5M | $312.5M | ||
| Q2 24 | $376.4M | $302.6M |
总债务CLVTICUI
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | — | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — |
股东权益CLVTICUI
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.8B | $2.1B | ||
| Q3 25 | $4.9B | $2.1B | ||
| Q2 25 | $5.0B | $2.1B | ||
| Q1 25 | $5.0B | $2.0B | ||
| Q4 24 | $5.1B | $2.0B | ||
| Q3 24 | $5.5B | $2.0B | ||
| Q2 24 | $5.6B | $2.0B |
总资产CLVTICUI
| Q1 26 | $10.9B | — | ||
| Q4 25 | $11.1B | $4.1B | ||
| Q3 25 | $11.2B | $4.1B | ||
| Q2 25 | $11.4B | $4.1B | ||
| Q1 25 | $11.5B | $4.2B | ||
| Q4 24 | $11.5B | $4.2B | ||
| Q3 24 | $12.0B | $4.3B | ||
| Q2 24 | $12.1B | $4.3B |
负债/权益比CLVTICUI
| Q1 26 | 0.89× | — | ||
| Q4 25 | 0.89× | — | ||
| Q3 25 | 0.90× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 0.88× | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.83× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.7M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $78.9M | $36.0M |
| 自由现金流率自由现金流/营收 | 13.5% | 6.6% |
| 资本支出强度资本支出/营收 | 9.5% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $333.9M | $91.8M |
8季度趋势，按日历期对齐
经营现金流CLVTICUI
| Q1 26 | $134.7M | — | ||
| Q4 25 | $159.9M | $60.6M | ||
| Q3 25 | $181.1M | $56.7M | ||
| Q2 25 | $116.3M | $11.2M | ||
| Q1 25 | $171.2M | $51.3M | ||
| Q4 24 | $141.3M | $40.2M | ||
| Q3 24 | $202.9M | $36.1M | ||
| Q2 24 | $126.2M | $82.0M |
自由现金流CLVTICUI
| Q1 26 | $78.9M | — | ||
| Q4 25 | $89.2M | $36.0M | ||
| Q3 25 | $115.5M | $27.6M | ||
| Q2 25 | $50.3M | $-8.5M | ||
| Q1 25 | $110.3M | $36.7M | ||
| Q4 24 | $59.1M | $16.1M | ||
| Q3 24 | $126.3M | $16.2M | ||
| Q2 24 | $60.3M | $62.5M |
自由现金流率CLVTICUI
| Q1 26 | 13.5% | — | ||
| Q4 25 | 14.5% | 6.6% | ||
| Q3 25 | 18.5% | 5.1% | ||
| Q2 25 | 8.1% | -1.5% | ||
| Q1 25 | 18.6% | 6.1% | ||
| Q4 24 | 8.9% | 2.6% | ||
| Q3 24 | 20.3% | 2.7% | ||
| Q2 24 | 9.3% | 10.5% |
资本支出强度CLVTICUI
| Q1 26 | 9.5% | — | ||
| Q4 25 | 11.5% | 4.6% | ||
| Q3 25 | 10.5% | 5.4% | ||
| Q2 25 | 10.6% | 3.6% | ||
| Q1 25 | 10.3% | 2.4% | ||
| Q4 24 | 12.4% | 3.8% | ||
| Q3 24 | 12.3% | 3.4% | ||
| Q2 24 | 10.1% | 3.3% |
现金转化率CLVTICUI
| Q1 26 | — | — | ||
| Q4 25 | 51.58× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
